On Jun. 12, 2020, the U.S. Food and Drug Administration (FDA) approved ViiV Healthcare’s Tivicay (dolutegravir) tablets and Tivicay PD (dolutegravir) tablets for suspension to treat HIV-1 infection in pediatric patients at least four weeks old and weighing at least 3 kg (6.61 pounds) in combination with other antiretroviral treatments.

According to the CDC, at the end of 2016, there were 2,238 children younger than 13 years old living with HIV in the U.S. and dependent areas. Effective treatment is important in reducing the amount of virus in the blood.